Poalim Ibi (PIU) - Total Liabilities

Latest as of December 2019: ILA33.81 Million ILA ≈ $90.65K USD

Based on the latest financial reports, Poalim Ibi (PIU) has total liabilities worth ILA33.81 Million ILA (≈ $90.65K USD) as of December 2019. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore PIU net asset momentum to track the company's year-over-year net asset growth rate.

Poalim Ibi - Total Liabilities Trend (2009–2019)

This chart illustrates how Poalim Ibi's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Poalim Ibi generate to measure how efficiently the company converts operating cash flow to free cash.

Poalim Ibi Competitors by Total Liabilities

The table below lists competitors of Poalim Ibi ranked by their total liabilities.

Company Country Total Liabilities
Keyang Elec Ma
KO:012200
Korea ₩191.85 Billion
Unifi Inc
NYSE:UFI
USA $160.50 Million
MANUKA RESOURCES LTD
F:6M0A
Germany €44.13 Million
WINS Co. Ltd
KQ:136540
Korea ₩23.42 Billion
Lytix Biopharma AS
OL:LYTIX
Norway Nkr19.77 Million
Central Plains Bancshares, Inc. Common Stock
NASDAQ:CPBI
USA $447.98 Million
Great Elm Capital Corp
NASDAQ:GECC
USA $175.29 Million
Shanghai Shibei Hi-Tech Co Ltd B
SHG:900902
China $12.13 Billion

Liability Composition Analysis (2009–2019)

This chart breaks down Poalim Ibi's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Poalim Ibi stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 5.42 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.25 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.20 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Poalim Ibi's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Poalim Ibi (2009–2019)

The table below shows the annual total liabilities of Poalim Ibi from 2009 to 2019.

Year Total Liabilities Change
2019-12-31 ILA33.81 Million
≈ $90.65K
+128.17%
2018-12-31 ILA14.82 Million
≈ $39.73K
-20.62%
2017-12-31 ILA18.67 Million
≈ $50.05K
-14.61%
2016-12-31 ILA21.86 Million
≈ $58.61K
+82.88%
2015-12-31 ILA11.95 Million
≈ $32.05K
-15.66%
2014-12-31 ILA14.17 Million
≈ $38.00K
+30.34%
2013-12-31 ILA10.87 Million
≈ $29.15K
+132.75%
2012-12-31 ILA4.67 Million
≈ $12.53K
-20.68%
2011-12-31 ILA5.89 Million
≈ $15.79K
-33.21%
2010-12-31 ILA8.82 Million
≈ $23.64K
-4.29%
2009-12-31 ILA9.21 Million
≈ $24.70K
--

About Poalim Ibi

TA:PIU Israel Investment Banking & Investment Services
Market Cap
$73.68 Million
ILA27.48 Billion ILA
Market Cap Rank
#20353 Global
#268 in Israel
Share Price
ILA1189.00
Change (1 day)
-0.34%
52-Week Range
ILA960.00 - ILA1845.00
All Time High
ILA1845.00
About

Poalim I.B.I.-Managing & Underwriting Ltd operates as an investment banking company. The company engages in the issuance of issues for corporations seeking to raise capital and debt in the capital market; management of issues, including distribution and management of consortium underwriters for issues of companies offering securities to the public; deals in brokerage of securities; and management… Read more